-
1Academic Journal
Συγγραφείς: V. O. Bitsadze, E. V. Slukhanchuk, J. Kh. Khizroeva, M. V. Tretyakova, V. I. Tsibizova, N. R. Gashimova, I. A. Nakaidze, I. Elalamy, J.-C. Gris, A. D. Makatsariya, В. О. Бицадзе, Е. В. Слуханчук, Д. Х. Хизроева, М. В. Третьякова, В. И. Цибизова, Н. Р. Гашимова, И. А. Накаидзе, И. Элалами, Ж.-К. Гри, А. Д. Макацария
Συνεισφορές: The review was funded by RFBR, project number 20-04-60274., Обзор выполнен при финансовой поддержке РФФИ в рамках научного проекта РФФИ №20-04-60274.
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 16, No 2 (2022); 158-175 ; Акушерство, Гинекология и Репродукция; Vol 16, No 2 (2022); 158-175 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: антикоагулянты, antidote, direct thrombin inhibitors, factor Xa inhibitors, warfarin, heparin, low molecular weight heparins, anticoagulants, антидот, прямые ингибиторы тромбина, ингибиторы Xa фактора, варфарин, гепарин, низкомолекулярные гепарины
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1319/1009; https://www.gynecology.su/jour/article/view/1319/1012; Lopes L., Spencer F.A., Neumann I. et al. Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and metaanalysis. Clin Pharmacol Ther. 2013;94(3):367–75. https://doi.org/10.1038/clpt.2013.99.; Chai-Adisaksopha C., Crowther M., Isayama T., Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8. https://doi.org/10.1182/blood-2014-07-590323.; Garcia D.A., Baglin T.P., Weitz J.I., Samama M.M. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S–e43S. https://doi.org/10.1378/chest.11-2291.; Buller H.R., Davidson B.L., Decousus H. et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867–73. https://doi.org/10.7326/0003-4819-140-11-200406010-00007.; Beyer-Westendorf J., Michalski F., Tittl L. et al. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Lancet Haematol. 2016;3(10):e480–e488. https://doi.org/10.1016/S2352-3026(16)30111-9.; Gong I.Y., Schwarz U.I., Crown N. et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PloS One. 2011;6(11):e27808. https://doi.org/10.1371/journal.pone.0027808.; Pirmohamed M., Burnside G., Eriksson N. et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294– 303. https://doi.org/10.1056/NEJMoa1311386.; Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994–3018. https://doi.org/10.1161/01.cir.103.24.2994.; Olsson S.B., Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691–8. https://doi.org/10.1016/s0140-6736(03)14841-6.; Stangier J., Rathgen K., Stahle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303. https://doi.org/10.1111/j.1365-2125.2007.02899.x.; Eriksson B.I., Dahl O.E., Huo M.H. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost. 2011;105(4):721–9. https://doi.org/10.1160/TH10-10-0679.; Eriksson B., Dahl O., Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85. https://doi.org/10.1111/j.1538-7836.2007.02748.x.; Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52. https://doi.org/10.1056/NEJMoa0906598.; Schulman S., Kearon C., Kakkar A.K. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18. https://doi.org/10.1056/NEJMoa1113697.; Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.; Samama M.M. The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thromb Res. 2011;127(6):497–504. https://doi.org/10.1016/j.thromres.2010.09.008.; Kakkar A.K., Brenner B., Dahl O.E. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–9. https://doi.org/10.1016/S0140-6736(08)60880-6.; Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular Atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.; Lassen M.R., Raskob G.E., Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807–15. https://doi.org/10.1016/S0140-6736(09)62125-5.; Lassen M.R., Gallus A., Raskob G.E. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–98. https://doi.org/10.1056/NEJMoa1006885.; Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.; Agnelli G., Buller H.R., Cohen A. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. https://doi.org/10.1056/NEJMoa1302507.; Hokusai-VTE Investigators; Buller H.R., Decousus H., Grosso M.A. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15. https://doi.org/10.1056/NEJMoa1306638.; Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907.; Weitz J.I., Chan N.C. Advances in antithrombotic therapy. Arterioscler Thromb Vasc Biol. 2019;39(1):7–12. https://doi.org/10.1161/ ATVBAHA.118.310960.; Pirlog A.-M., Pirlog C.D., Maghiar M.A. DOACs vs vitamin K antagonists: a comparison of phase III clinical trials and a prescriber support tool. Open Access Maced J Med Sci. 2019;7(7):1226–32. https://doi.org/10.3889/oamjms.2019.289.; Hellenbart E.L., Faulkenberg K.D., Finks S.W. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag. 2017;13:325–42. https://doi.org/10.2147/VHRM.S121661.; Wheeler A.P., Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol. 2016;9(7):629–37. https://doi.org/10.1080/17474086.2016.1191944.; Gomez K., Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008;14(6):1183–9. https://doi.org/10.1111/j.1365-2516.2008.01667.x.; Preis M., Hirsch J., Kotler A. et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210–5. https://doi.org/10.1182/blood-2016-09742262.; Georgi B., Mielke J., Chaffin M. et al. Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI. Stroke. 2019;50(11):3004–12. https://doi.org/10.1161/STROKEAHA.119.026545.; Mavromanoli A.C., Barco S., Konstantinides S.V. Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition. Res Pract Thromb Haemost. 2021;5(4):10.1002/rth2.12509. https://doi.org/10.1002/rth2.12509.; Yau J.W., Liao P., Fredenburgh J.C. et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102–7. https://doi.org/10.1182/blood-2013-12-540872.; Crosby J.R., Marzec U., Revenko A.S. et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol. 2013;33(7):1670–8. https://doi.org/10.1161/ATVBAHA.113.301282.; Buller H.R., Bethune C., Bhanot S. et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–40. https://doi.org/10.1056/NEJMoa1405760.; Eikelboom J., Floege J., Thadhani R. et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int. 2021;100(6):1199–207. https://doi.org/10.1016/j.kint.2021.08.028.; Verhamme P., Yi B.A., Segers A. et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385(7):609–17. https://doi.org/10.1056/NEJMoa2105872.; Weitz J.I., Bauersachs R., Becker B. et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130–9. https://doi.org/10.1001/jama.2019.20687.; Eikelboom J.W., Connolly S.J., Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14. https://doi.org/10.1056/NEJMoa1300615.; Jaffer I.H., Stafford A.R., Fredenburgh J.C. et al. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc. 2015;4(8):e002322. https://doi.org/10.1161/JAHA.115.002322.; Bethune C., Walsh M., Jung B. et al. Pharmacokinetics and pharmacodynamics of Ionis-FXIRx, an antisense inhibitor of factor XI, in patients with end-stage renal disease on hemodialysis. Blood. 2017;130(Suppl 1):1116. https://doi.org/10.1182/BLOOD.V130.SUPPL_1.1116.1116.; Kearon C., Akl E.A., Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52. https://doi.org/10.1016/j.chest.2015.11.026.; Tripodi A. D-dimer testing in laboratory practice. Clin Chem. 2011;57(9):1256–62. https://doi.org/10.1373/clinchem.2011.166249.; Palareti G., Cosmi B., Legnani C. et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780–9. https://doi.org/10.1056/NEJMoa054444.; Douketis J., Tosetto A., Marcucci M. et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153(8):523–31. https://doi.org/10.7326/0003-4819-153-8-201010190-00009.; Palareti G., Cosmi B., Legnani C. et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014;124(2):196–203. https://doi.org/10.1182/blood-2014-01-548065.; Rodger M.A., Kahn S.R., Wells P.S. et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417–26. https://doi.org/10.1503/cmaj.080493.; Douxfils J., Gosselin R.C. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017;43(3):277–90. https://doi.org/10.1055/s-0036-1597296.; Schulman S., Kearon C., Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.; Kaatz S., Ahmad D., Spyropoulos A., Schulman S., Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. https://doi.org/10.1111/jth.13140.; Douketis J.D., Arneklev K., Goldhaber S.Z. et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med. 2006;166(8):853–9. https://doi.org/10.1001/archinte.166.8.853.; Schulman S., Beyth R.J., Kearon C., Levine M.N. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6):257S–298S. https://doi.org/10.1378/chest.08-0674.; Crowther M., Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med. 2007;13(5):409– 13. https://doi.org/10.1097/MCP.0b013e328216430d.; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S., Mehta S.R., Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464–76. https://doi.org/10.1056/NEJMoa055443.; Yusuf S., Mehta S.R., Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519–30. https://doi.org/10.1001/jama.295.13.joc60038.; Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162(16):1833–40. https://doi.org/10.1001/archinte.162.16.1833.; Reilly P.A., Lehr T., Haertter S. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–8. https://doi.org/10.1016/j.jacc.2013.07.104.; Connolly S.J., Wallentin L., Ezekowitz M.D. et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128(3):237–43. https://doi.org/10.1161/CIRCULATIONAHA.112.001139.; Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634–40. https://doi.org/10.1161/CIRCULATIONAHA.112.115386.; Halperin J.L., Halperin JL, Wojdyla D. et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–46. https://doi.org/10.1161/CIRCULATIONAHA.113.005008.; Crowther M.A., Douketis J.D., Schnurr T. et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. Ann Intern Med. 2002;137(4):251–4. https://doi.org/10.7326/0003-4819-137-4-200208200-00009.; DeZee K.J., Shimeall W.T., Douglas K.M. et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166(4):391–7. https://doi.org/10.1001/.391.; Watson H.G., Baglin T., Laidlaw S.L. et al. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115(1):145–9. https://doi.org/10.1046/j.1365-2141.2001.03070.x.; Holbrook A., Schulman S., Witt D.M. et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S– e184S. https://doi.org/10.1378/chest.11-2295.; Makris M., Greaves M., Phillips W.S. et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77(3):477–80.; Holland .L, Warkentin T.E., Refaai M. et al. Suboptimal effect of a threefactor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171–7. https://doi.org/10.1111/j.1537-2995.2008.02080.x.; Dentali F., Marchesi C., Pierfranceschi M.G. et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106(3):429–38. https://doi.org/10.1160/TH11-01-0052.; Nishijima D.K., Dager W.E., Schrot R.J., Holmes J.F. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med. 2010;17(3):244– 51. https://doi.org/10.1111/j.1553-2712.2010.00666.x.; Pinner N.A., Hurdle A.C., Oliphant C. et al. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg. 2010;74(6):631–5. https://doi.org/10.1016/j.wneu.2010.06.030.; Levi M., Levy J.H., Andersen H.F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791–800. https://doi.org/10.1056/NEJMoa1006221.; Wojcik C., Schymik M.L., Cure E.G. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009;2(4):217–25. https://doi.org/10.1007/s12245-009-0125-8.; Pai M., Crowther M.A. Neutralization of heparin activity. Handb Exp Pharmacol. 2012;(207):265-77. https://doi.org/10.1007/978-3-64223056-1_11.; van Veen J.J., Maclean R.M., Hampton K.K. et al. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis. 2011;22(7):565–70. https://doi.org/10.1097/MBC.0b013e3283494b3c.; Nybo M., Madsen J.S. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103(2):192–6. https://doi.org/10.1111/j.1742-7843.2008.00274.x.; Horrow J.C. Protamine: a review of its toxicity. Anesth Analg. 1985;64(3):348–61.; Bakchoul T., Zollner H., Amiral J. et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood. 2013;121(15):2821–7. https://doi.org/10.1182/blood-2012-10-460691.; Longstaff C., Hogwood J., Gray E. et al. Neutralization of the anticoagulant effects of heparin by histones in blood plasma and purified systems. Thromb Haemost. 2016;115(3):591–9. https://doi.org/10.1160/TH15-03-0214.; Chan S., Kong M., Minning D. et al. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost. 2003;1(4):760–5. https://doi.org/10.1046/j.1538-7836.2003.00101.x.; Lauritzen B., Hedner U., Johansen P. et al. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J Thromb Haemost. 2008;6(5):804–11. https://doi.org/10.1111/j.1538-7836.2008.02933.x.; Bijsterveld N.R., Moons A.H., Boekholdt S.M. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106(20):2550–4. https://doi.org/10.1161/01.cir.0000038501.87442.02.; Bijsterveld N.R., Vink R., van Aken B.E. et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004;124(5):653–8. https://doi.org/10.1111/j.1365-2141.2003.04811.x.; Firozvi K., Deveras R.A.E., Kessler C.M. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol. 2006;81(8):582–9. https://doi.org/0.1002/ajh.2065.; Nagler M., Haslauer M., Wuillemin W.A. Fondaparinux – data on efficacy and safety in special situations. Thromb Res. 2012;129(4):407–17. https://doi.org/10.1016/j.thromres.2011.10.037.; Gerotziafas G.T., Depasse F., Chakroun T. et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost. 2004;91(3):531–7. https://doi.org/10.1160/TH03-07-0483.; Lisman T., Bijsterveld N., Adelmeijer J. et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost. 2003;1(11):2368–73. https://doi.org/10.1046/j.1538-7836.2003.00536.x.; Akwaa F., Spyropoulos A.C. Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. Curr Treat Options Cardiovasc Med. 2013;15(3):288–98. https://doi.org/10.1007/s11936013-0238-5.; van Ryn J., Stangier J., Haertter S. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27. https://doi.org/10.1160/TH09-11-0758.; Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259–68. https://doi.org/10.2165/11318170-000000000-00000.; Khadzhynov D., Wagner F., Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013;109(4):596–605. https://doi.org/10.1160/TH12-08-0573.; Zhou W., Schwarting S., Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42(12):3594–9. https://doi.org/10.1161/STROKEAHA.111.624650.; Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9. https://doi.org/10.1161/CIRCULATIONAHA.111.029017.; Marlu R., Hodaj E., Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost. 2012;108(2):217–24. https://doi.org/10.1160/TH12-03-0179.; Dager W.E., Gosselin R.C., Roberts A.J. Reversing dabigatran in lifethreatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013;41(5):e42–6. https://doi.org/10.1097/CCM.0b013e31827caaa3.; Schulman S., Ritchie B., Goy J.K. et al. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol. 2014;164(2):308–10. https://doi.org/10.1111/bjh.12620.; van Ryn J., Schurer J., Kink-Eiband M., Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood. 2011;118(21):2316. https://doi.org/10.1182/blood.V118.21.2316.2316.; Pollack C.V., Reilly P.A., van Ryn J. et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431–41. https://doi.org/10.1056/NEJMoa1707278.; Zhang D., Frost C.E., He K. et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013;41(4):906–15. https://doi.org/10.1124/dmd.112.050575.; Godier A., Miclot A., Le Bonniec B. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116(1):94–102. https://doi.org/10.1097/ALN.0b013e318238c036.; Fukuda T., Honda Y., Kamisato C. et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107(2):253–9. https://doi.org/10.1160/TH11-090668.; Majeed A., Agren A., Holmstrom M. et al. Management of rivaroxabanor apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017;130(15):1706–12. https://doi.org/10.1182/blood-2017-05-782060.; Schulman S., Gross P.L., Ritchie B. et al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemosts. 2018;118(5):842–51. https://doi.org/10.1055/s-0038-1636541.; Gruber A., Marzec U.M., Buetehorn U., Hanson S., Perzborn E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood. 2008;112(11):3825. https://doi.org/10.1182/blood.V112.11.3825.3825.; Lu G., DeGuzman F.R., Hollenbach S.J. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51. https://doi.org/10.1038/nm.3102.; Mark C., Kitt M.M., Vandana M. et al. A phase 2 randomized, doubleblind, placebo-controlled trial demonstrating reversal of rivaroxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood. 2013;122(21):3636. https://doi.org/10.1182/BLOOD.V122.21.3636.3636.; Connolly S.J., Crowther M., Eikelboom J.W. et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–35. https://doi.org/10.1056/NEJMoa1814051.; Laulicht B., Bakhru S., Lee C. et al. Small molecule antidote for anticoagulants. Circulation. 2012;126(Suppl 1):11395.; HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10241):1927– 36. https://doi.org/10.1016/S0140-6736(20)30848-5.; Hemphill J.C., Greenberg S.M., Anderson C.S. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032–60. https://doi.org/10.1161/STR.0000000000000069.; Lansberg M.G., O'Donnell M.J., Khatri P. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S–e636S. https://doi.org/10.1378/chest.11-2302.; Pennlert J., Overholser R., Asplund K. et al. Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke. 2017;48(2):314–20. https://doi.org/10.1161/STROKEAHA.116.014643.; Nielsen P.B., Larsen T.B., Skjoth F., Lip G.Y. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med. 2017;177(4):563–70. https://doi.org/10.1001/jamainternmed.2016.9369.; Gralnek I.M., Dumonceau J.-M., Kuipers E.J. et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1–a46. https://doi.org/10.1055/s-0034-1393172.; Majeed A., Wallvik N., Eriksson J. et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. Thromb Haemost. 2017;117(3):491–9. https://doi.org/10.1160/TH16-07-0498.; https://www.gynecology.su/jour/article/view/1319
-
2Academic Journal
Συγγραφείς: A. V. Vorobyov, A. D. Makatsariya
Πηγή: Медицинский совет, Vol 0, Iss 2, Pp 79-85 (2016)
Θεματικοί όροι: низкомолекулярный гепарин, thrombosis prophylaxis, low molecular weight heparin, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, гепарин-индуцированная тромбоцитопения профилактика тромбозов, fact, Medicine, oral anticoagulants, heparin-induced thrombocytopenia, пероральные антикоагулянты, ингибиторы xa-фактора
Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/45/45
https://doaj.org/article/b961a93b89ed4f25a128fd7b8560eca3
https://www.med-sovet.pro/jour/article/view/45
https://cyberleninka.ru/article/n/patogeneticheskie-osobennosti-profilaktiki-trombogemorragicheskih-oslozhneniy-u-onkoginekologicheskih-bolnyh
https://www.med-sovet.pro/jour/article/viewFile/45/45 -
3Academic Journal
Συγγραφείς: A. V. Vorobev, A. M. Chabrov, A. A. Savchenko, A. D. Makatsariya, А. В. Воробьёв, А. М. Чабров, А. А. Савченко, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 10, No 1 (2016); 26-37 ; Акушерство, Гинекология и Репродукция; Vol 10, No 1 (2016); 26-37 ; 2500-3194 ; 2313-7347 ; 10.17749/2313-7347.2016.10.1
Θεματικοί όροι: ингибиторы Xa-фактора, oral anticoagulants, heparin-indused thrombocytopenia, thrombosis prophylaxis, anti- Xa drugs, пероральные антикоагулянты, гепарин-индуцированная тромбоцитопения, профилактика тромбозов
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/33/523; Воробьёв А.В. Злокачественные заболевания и тромбозы. Вопросы акушерства, гинекологии и перинатологии. 2008; 2 (7): 18-25.; Макацария А.Д., Воробьёв А.В., Чабров А.М. Значение оценки маркеров тромбофилии при проведении химио- и лучевой терапии у онкологических больных. Материалы Российского Медицинского форума – 2006 «Фундаментальная наука и практика», 18-20 октября 2006 г.; Макацария А.Д., Воробьёв А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы. М. 2008; 650 с.; Макацария А.Д. и соавт. Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей под редакцией А.Д. Макацария. М. 2011.; Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Ассоциация флебологов России, Всероссийское общество хирургов. М. 2010.; Цыб А.Ф., Сушкевич Г.Н., Балуда М.В., Воробьёв А.В., Чабров А.М. Принципы профилактики тромботических осложнений у онкологических больных (солидные образования). Пособие для врачей. Обнинск. 2008; 42 стр.; Шилова А.Н., Лазарев А.Ф., Воробьёв П.А., Баркаган З.С., Ходоренко С.А., Котовщикова Е.Ф., Момот А.П., Буевич Е.И. Контролируемая антитромботическая профилактика онкотромбозов: клинико-экономический анализ. Сибирский онкологический журнал. 2008; 3: 74-76; Agnes Y.Y. Lee, M.D., Mark N. Levine, M.D., Ross I. Baker, M.D., Chris Bowden, M.D., Ajay K. Kakkar, M.B., Martin Prins, M.D., Frederick R. Rickles, M.D., Jim A. Julian, M.Math., Susan Haley, B.Sc., Michael J. Kovacs, M.D., Michael Gent. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2003; 349: 146-153.; Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003; 22: 6524-36.; David Bergqvist, Giancarlo Agnelli, Alexander T. Cohen, Amiram Eldor, Paul E. Nilsson, Anne Le Moigne-Amrani, Flavia Dietrich-Neto F. ENOXACAN II Investigators. Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer. N; Engl J Med. 2002; 346: 975-980.; Drugs. Establishing Active Ingredient Sameness for Generic Enoxaparin Sodium, a Low Molecular Weight Heparin. 2010 July 28.; Donati M.B., A. Falanga: Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol. 2001; 106: 18-24.; EMEA. Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/BMWP/11826407enfin.pdf. 2010 July 29.; Falanga A., Marchetti M., Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer. 2004; 30: 11-23.; FDA News Release. fda.gov/NewsEvents/Newsroorn/PressAnnouncements/ucm220092.hm. Дата обращения: 23.07.2015.; Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecularweight heparin. Thromb Haemost. 2008; 99: 807-18.; Gray E., Rigsby P., Behr-Gross M.E. Collaborative study to establish the lowmolecular- mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio. 2004; 1: 59-76.; Guerrini M., Guglieri S., Naggi A., Sasisekharan R., Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost. 2007; 33: 478-87.; Harenberg J., Kakkar A., Bergqvist D. et al. On behalf of the Subcommittee on Control of Anticoagulalion of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemoslasis. Recommendations on biosimiliar lowmolecular- weight heparins. J ThrombHaemost. 2009; 7 (7): 1222-1225.; Hirsh J., Warkentin T.E., Shaughnessy S.G. et al: Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119: Suppl. 1: 64-94.; Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol. 2004; 22 (10): 1944-1948.; Kalodiki E., Leon W. SASAT and Task Force on Generic LMWHs. SASAT (South Asian Society on Atherosclerosis and Thrombosis) proposal for regulatory guidelines for generic low molecular weight heparins (LMWHs). Clin Appl Thromb Hemost. 2009; 15 (1): 8-11.; Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005; 23 (10): 2130-2135.; Lee AYY. Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost. 2003; 1: 2273-2274.; Meyer G., Marjanovic Z., Valcke J. et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer a randomized controlled study. Arch. Intern. Med. 2002; 162 (15): 1729-1735.; New Oral Anticoagulants and the Cancer Patient theoncologist.com/article/new-oralanticoagulants-and-cancer-patient.; New Anticoagulants: Anti IIa vs Anti Xa-Is One Better? Kenneth A. Bauer MD. Journal of Thrombosis and Thrombolysis. February 2006; 21 (1): 67-72.; North American Thrombosis Forum Official Policy Statement regarding the protection of patient safety and patient rights on the matter of follow-on biologies. natfonIine.org/ NATFbiologiessta-tement.php. Дата обращения: 26.07.2010.; Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484- 3488.; Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism.; Lancet Oncol. 2005 Jun; 6 (6): 401-10.; Prandoni P., Lensing A.W., Buller H.R. et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 1992; 327 (16): 1128-1133.; Samama M.M., Gerotziafas G. Comparative Pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000; 26: 31-6.; Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000; 160: 3415-20.; van Dongen C.J., Mac Gillavry M.R., Prins M.H. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. 2005; 3. Art. № CD003074.; WHO 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). who.int/biologicaIs/areas/biologicaI_thcrapeutic/BIOTHERAPETUTICS_FOR_WEB_22APRIL2010_WI. Дата обращения: 18.08.2015.; Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis. 2003; 29: 239-46.; https://www.gynecology.su/jour/article/view/33
-
4Academic Journal
Συγγραφείς: Воробьев, А., Макацария, А.
Θεματικοί όροι: НИЗКОМОЛЕКУЛЯРНЫЙ ГЕПАРИН, ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ, ГЕПАРИН-ИНДУЦИРОВАННАЯ ТРОМБОЦИТО-ПЕНИЯ, ПРОФИЛАКТИКА ТРОМБОЗОВ, ИНГИБИТОРЫ XA-ФАКТОРА
Περιγραφή αρχείου: text/html
-
5Academic Journal
Πηγή: Практическая медицина.
Θεματικοί όροι: НИЗКОМОЛЕКУЛЯРНЫЙ ГЕПАРИН, ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ, ГЕПАРИН-ИНДУЦИРОВАННАЯ ТРОМБОЦИТО-ПЕНИЯ, ПРОФИЛАКТИКА ТРОМБОЗОВ, ИНГИБИТОРЫ XA-ФАКТОРА, 3. Good health
Περιγραφή αρχείου: text/html
